Lipe & Dalton’s Eli Lilly LLY Stock Holding History

Lipe & Dalton’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$15K	Hold	13	–	–	0.01%	93
2026 Q2	$16K	Hold	13	–	–	0.01%	93
2026 Q1	$12K	Hold	13	–	–	0.01%	91
2025 Q4	$14K	Buy	+13	New	+$12.4K	0.01%	94
2024 Q4	–	Sell	-45	Closed	-$40K	–	99
2024 Q3	$40K	Sell	45 -11	-20%	-$9.9K	0.02%	97
2024 Q2	$51K	Hold	56	–	–	0.03%	93
2024 Q1	$44K	Buy	56 +11	+24%	+$7.83K	0.02%	97
2023 Q4	$26K	Buy	+45	New	+$26.3K	0.01%	98
2021 Q1	–	Sell	-100	Closed	-$17K	–	102
2020 Q4	$17K	Hold	100	–	–	0.01%	96
2020 Q3	$15K	Hold	100	–	–	0.01%	94
2020 Q2	$16K	Hold	100	–	–	0.01%	93
2020 Q1	$14K	Hold	100	–	–	0.01%	95
2019 Q4	$13K	Hold	100	–	–	0.01%	103
2019 Q3	$11K	Sell	100 -10	-9%	-$1.11K	0.01%	104
2019 Q2	$12K	Hold	110	–	–	0.01%	97
2019 Q1	$14K	Buy	+110	New	+$13.4K	0.01%	77

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $104B AUM 51.65% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $39.3B AUM 31.81% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Lipe & Dalton's LLY Position: Q3 2026 in Review

Lipe & Dalton held its Eli Lilly (LLY) position steady in Q3 2026 at 13 shares worth $15K. The position accounts for 0.01% of the portfolio, ranked #93.

Lipe & Dalton first reported a position in LLY in Q1 2019 and has held it in 16 quarters since. The position peaked at $51K in Q2 2024. 2,264 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

Lipe & Dalton held 13 shares of Eli Lilly worth $15K as of Q3 2026.
Lipe & Dalton left its Eli Lilly share count unchanged in Q3 2026.
Eli Lilly made up 0.01% of Lipe & Dalton's portfolio in Q3 2026, its #93 holding.
Lipe & Dalton first reported a position in Eli Lilly in Q1 2019 and has held it in 16 quarters since.
Lipe & Dalton's Eli Lilly position peaked at $51K in Q2 2024.
2,264 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Lipe & Dalton's 13F filing for Q3 2026, filed 15 Oct 2026.